<h4>Aim</h4>To evaluate pregnancy and post-delivery outcomes with non-automated insulin pumps or multiple daily injections (MDI) in women with type 1 diabetes (T1D).<h4>Methods</h4>A preplanned secondary analysis of the CopenFast trial including women with T1D using continuous glucose monitoring (CGM), primarily intermittently scanned CGM, routinely. The gene discussed is INS; the disease is type 1 diabetes mellitus.